CRISPR quality control testing firm CRISPR QC and Cardea Bio have launched CRISPR-BIND, a rapid and highly sensitive tool to characterize guide RNA and CRISPR-Cas interactions. CRISPR-BIND is the first product in a suite of quality control capabilities, and is built on Cardea's biology-gated transistors and an automated, high-throughput liquid handler to generate highly sensitive electronic signals that allow for rapid assessments of gRNA-Cas interactions directly at the bench. This includes, but is not limited to, monitoring the interactions and stability of a variety of modified gRNAs with engineered Cas enzymes.
CRISPR QC will commercialize CRISPR-BIND in the US in partnership with COBO Technologies, which will offer the product in Europe, the firms said. CRISPR QC is Cardea's first commercial partner and CRISPR-BIND is the first of a series of CRISPR QC applications that they expect to come out of the partnership.